Daxor Director Awarded 2,500 Stock Options at $9.29 Vesting 2025-27
Daxor (NASDAQ:DXR) filed a Form 4 reporting the grant of 2,500 non-qualified stock options to director Joy S. Goudie on June 24 2025 at an exercise price of $9.29 per share, expiring June 24 2030.
Rhea-AI Filing Summary
Daxor (NASDAQ:DXR) filed a Form 4 reporting the grant of 2,500 non-qualified stock options to director Joy S. Goudie on June 24 2025 at an exercise price of $9.29 per share, expiring June 24 2030.
The award is contingent upon SEC approval of an amendment to the company’s 2020 Incentive Compensation Plan and vests in three tranches: 833 options on June 24 2025, 883 on June 24 2026, and 834 on June 24 2027. No open-market purchases or sales were disclosed; the filing solely records the new derivative position. Following the transaction, Goudie beneficially owns 2,500 options with no change to her reported direct share ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) | 2,500 | $0.00 | $0.00 |
Footnotes (2)
- F1. Stock options granted on June 24, 2025 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan").
- F2. The stock options will vest in three installments on June 24, 2025 (833), June 24, 2026 (883) and June 24, 2027 (834)
FAQ
How many stock options did DXR grant to director Joy S. Goudie?
What is the vesting schedule for Joy Goudie’s 2,500 DXR options?
Are the granted options subject to any conditions?
AI-generated analysis. How Rhea-AI works. Not financial advice.